Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-02-06
Target enrollment:
Participant gender:
Summary
This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and
safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+,
HER2-negative advanced (recurrent or metastatic) breast cancer. Patients were treated with
daily doses of 600 mg ribociclib (3-weeks-on/1-week-off schedule) in combination with 2.5 mg
letrozole daily (continuous dosing). Dose adjustments (dose reduction or interruption)
according to safety findings were allowed.